The Preimplantation Genetic Testing Market focuses on genetic testing performed on embryos created through assisted reproductive technologies before an embryo is transferred to the uterus. The technology helps identify specific genetic abnormalities and supports fertility specialists and prospective parents in making informed embryo-selection decisions. Preimplantation genetic testing is increasingly being incorporated into fertility treatment programs as awareness of inherited disorders and reproductive health options continues to grow.
The market is gaining momentum because of rising infertility rates, increasing use of in vitro fertilization, growing awareness of hereditary conditions, and improvements in genetic analysis technologies. Next-generation sequencing, polymerase chain reaction, artificial intelligence, and other advanced analytical approaches are helping laboratories improve testing capabilities and efficiency. According to Market Research Future, the global market was valued at USD 2.11 billion in 2024 and is projected to increase from USD 2.26 billion in 2025 to USD 4.492 billion by 2035, representing a CAGR of 7.11% during 2025–2035. North America accounted for more than 42.65% of the market in 2024.
Get Free Sample PDF Brochure:
https://www.marketresearchfuture.com/sample_request/8121
Market Drivers
Rising Infertility Rates:
Infertility is affecting a substantial number of individuals and couples worldwide, increasing demand for assisted reproductive technologies. As more patients pursue IVF and related fertility treatments, the need for genetic evaluation of embryos is also increasing. PGT can provide additional information during the embryo-selection process and may be particularly relevant for couples concerned about inherited genetic conditions.
Growing Adoption of Assisted Reproductive Technologies:
The expansion of IVF and other assisted reproductive procedures is creating a broader clinical environment for preimplantation genetic testing. Fertility clinics are increasingly integrating genetic testing services into reproductive-care programs, allowing patients to access embryo screening alongside fertility treatment.
Increasing Awareness of Genetic Disorders:
Greater awareness of inherited diseases and chromosomal abnormalities is encouraging prospective parents to explore genetic testing options. Families with known genetic risks may seek testing to obtain additional information about embryos before implantation.
Advancements in Next-Generation Sequencing:
Next-generation sequencing has significantly expanded the ability of laboratories to analyze genetic information. Improvements in sequencing accuracy, processing speed, and analytical capabilities are supporting the development of more sophisticated preimplantation testing services. MRFR identifies technological advancements as a major factor influencing the market’s future development.
Increasing Demand for Personalized Reproductive Care:
Patients increasingly expect fertility treatment to be tailored to their individual medical and reproductive circumstances. Genetic information can contribute to personalized decision-making, creating opportunities for PGT providers and fertility clinics to offer more comprehensive reproductive solutions.
Growing Acceptance of Genetic Testing:
As genetic testing becomes more familiar to patients and healthcare professionals, acceptance of reproductive genetic testing is increasing. Greater public understanding can encourage prospective parents to discuss genetic screening options with fertility specialists and genetic counselors.
Market Challenges
High Cost of Testing:
Preimplantation genetic testing can add significant expenses to an IVF cycle. The cost of laboratory analysis, embryo biopsy, genetic testing, and related fertility procedures may limit access for patients who do not have adequate insurance coverage or financial resources.
Ethical and Social Considerations:
Testing embryos raises ethical questions surrounding embryo selection, genetic information, reproductive decision-making, and the potential future use of genetic technologies. These considerations can influence patient decisions and regulatory policies.
Complex Regulatory Environment:
Genetic testing and assisted reproductive technologies are subject to different regulations across countries and jurisdictions. Differences in regulatory requirements can make international expansion more complex for testing laboratories and fertility-service providers.
Requirement for Specialized Expertise:
PGT requires skilled embryologists, geneticists, laboratory specialists, fertility physicians, and genetic counselors. A shortage of appropriately trained professionals can restrict the availability of advanced testing services, particularly in emerging healthcare markets.
Limited Accessibility:
Advanced fertility and genetic testing services are concentrated in developed healthcare markets and major urban centers. Patients in rural or underserved regions may have limited access to specialized fertility clinics and genetic laboratories.
Browse In-depth Market Research Report on Preimplantation Genetic Testing Market:
Preimplantation Genetic Testing Market Research Report
Market Segmentation
By Application:
Diagnostic Testing: Diagnostic testing represents the largest application segment, accounting for approximately 52% of the market according to MRFR. It plays an important role in identifying genetic abnormalities in embryos and supporting embryo-selection decisions before implantation.
Carrier Screening: Carrier screening is gaining momentum as prospective parents increasingly seek information about inherited genetic risks. This segment is identified as one of the faster-growing areas of the market.
Embryo Selection: Embryo selection uses genetic and other available information to support fertility specialists when determining which embryos may be suitable for transfer. Increasing integration of genetic information into IVF protocols is supporting this segment.
By Technique:
Polymerase Chain Reaction: PCR-based approaches can amplify specific DNA sequences and are useful for analyzing targeted genetic conditions.
Next-Generation Sequencing: NGS provides extensive genetic information and has become an important technology within modern preimplantation testing. Its ability to analyze genetic material efficiently is supporting continued adoption.
Fluorescence In Situ Hybridization: FISH has historically been used to identify specific chromosomal abnormalities and remains part of the technological landscape for embryo testing.
Single Nucleotide Polymorphism: SNP-based techniques can provide detailed genetic information and support the analysis of inherited conditions and chromosomal characteristics.
By End Use:
Fertility Clinics: Fertility clinics represent the dominant end-use segment because PGT is closely integrated with IVF and embryo-transfer services. Clinics increasingly collaborate with specialized genetic laboratories to provide comprehensive reproductive-care solutions.
Research Laboratories: Research laboratories contribute to technological development, genetic research, testing-method validation, and innovation in reproductive genetics. Increased investment in genetic research is supporting the importance of this segment.
Hospitals: Hospitals with reproductive medicine and fertility departments may provide PGT as part of broader assisted reproductive and genetic counseling services.
By Client Type:
Individuals: Individuals and couples undergoing fertility treatment represent a major client group. Growing awareness of genetic risks and personalized reproductive options is encouraging more patients to discuss PGT with fertility specialists.
Healthcare Providers: Fertility specialists, reproductive endocrinologists, genetic counselors, and other healthcare professionals use genetic testing information to support patient counseling and embryo-selection decisions.
Healthcare Institutions: Hospitals, fertility networks, and other healthcare institutions may incorporate PGT into their reproductive medicine programs and establish partnerships with specialized genetic testing laboratories.
Regional Insights
North America:
North America is the leading regional market, holding more than 42.65% share in 2024. The region benefits from advanced fertility clinics, established genetic-testing infrastructure, high healthcare expenditure, and broad acceptance of assisted reproductive technologies. The North American market was valued at approximately USD 0.8 billion in 2024 and is projected to reach USD 1.75 billion by 2035.
Europe:
Europe represents another important market, supported by established reproductive healthcare systems, regulatory frameworks, and increasing awareness of genetic disorders. The European market was valued at approximately USD 0.6 billion in 2024 and is projected to reach USD 1.25 billion by 2035.
Asia-Pacific:
Asia-Pacific is emerging as a high-growth region as fertility services expand, healthcare expenditure rises, and awareness of reproductive genetic testing increases. The region is also benefiting from growing medical tourism and improvements in fertility-care infrastructure. MRFR estimates the APAC market at approximately USD 0.55 billion, with projections reaching USD 1.2 billion by 2035.
South America:
South America represents a developing opportunity for PGT providers. Increasing awareness of genetic testing, improving fertility services, and expanding access to assisted reproductive technologies are expected to support market development.
Middle East & Africa:
The Middle East and Africa currently represent a smaller portion of the global market. Limited access to specialized healthcare, differences in regulatory environments, and availability of advanced fertility services can restrict growth. However, improvements in healthcare infrastructure and growing awareness of reproductive medicine may create future opportunities.
Key Players
Illumina
Thermo Fisher Scientific
Fulgent Genetics
Natera
CooperSurgical
Preimplantation Genetic Diagnosis
Genea
Reproductive Health Technologies
Mayo Clinic
These companies and organizations compete through genetic-testing technologies, laboratory capabilities, fertility partnerships, research and development, service expansion, and improvements in testing accuracy. MRFR identifies Illumina, Thermo Fisher Scientific, Fulgent Genetics, Natera, and CooperSurgical among the major participants in the market.
Future Outlook
The Preimplantation Genetic Testing Market is expected to continue expanding as fertility treatments become more widely adopted and genetic testing becomes increasingly integrated into reproductive medicine. MRFR projects the market to reach approximately USD 4.492 billion by 2035, growing at a CAGR of 7.11% from 2025 to 2035.
Technological innovation will remain a central factor in the market’s development. Improvements in next-generation sequencing, molecular analysis, automation, and genetic-data interpretation can enhance the efficiency and capabilities of PGT laboratories.
Artificial intelligence is also expected to create new opportunities. AI-based analytical tools may help laboratories process large volumes of genetic information and support more efficient interpretation of testing results. MRFR specifically identifies AI-driven genetic analysis software as an emerging opportunity.
The expansion of fertility clinics and partnerships between genetic testing companies and reproductive healthcare providers is another important growth area. Bundled fertility and genetic-testing services may make it easier for patients to access comprehensive reproductive solutions.
Telehealth and remote genetic counseling can further improve accessibility. Digital consultations may help patients in locations without specialized genetic counselors obtain information before and after testing.
The growing focus on personalized medicine is likely to strengthen demand for reproductive genetic solutions. Prospective parents increasingly seek treatment approaches tailored to their medical history, genetic risks, and reproductive goals.
At the same time, ethical considerations, regulatory differences, affordability, and access to specialized expertise will continue to influence adoption. Providers that can combine technological accuracy with responsible counseling, regulatory compliance, and patient-centered services may be well positioned for future growth.
Overall, rising infertility rates, increasing adoption of IVF, greater awareness of hereditary diseases, advances in genetic technologies, personalized reproductive care, and expanding fertility infrastructure are expected to support the long-term Growth of the Preimplantation Genetic Testing Market.
Related Report:
Dive into related studies for a broader industry perspective:
Chronic Lower Back Pain Treatment Market Volume
Chronic Lower Back Pain Treatment Market Forecast
Chronic Lower Back Pain Treatment Market Outlook
Chronic Lower Back Pain Treatment Market Analysis
About Market Research Future:
Market Research Future (MRFR) is a global market research company providing market research and consulting services across healthcare, pharmaceuticals, biotechnology, medical devices, life sciences, technology, and other industries. Its research reports cover market size, segmentation, regional developments, competitive landscapes, emerging technologies, market trends, and future opportunities.
Follow Us:
LinkedIn | Twitter
Contact:
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)
